Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Patent Citations (12)

Non-Patent Literature (23)

• Sabnis et al. Inhibition of phosphatidylinositol 3-kinase/ AKT pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin. Cancer Res. 2007; 13: 2751-2757.Examiner
• Miller et al. Hyperactivation of phosphatdiylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. The Journal of Clinical Investigation. vol. 120, No. 7, Jul. 2010.Examiner
• Chou and Talalay, “Quantitative analysis of dose-effect relationships; the combined effects of multiple drugs or enzyme inhibitors” Adv Enzyme Regul. 22:27-55 ( 1984).Applicant
• Friedman et al., “Selective PI3K and dual P13K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models” Cancer Research—AACR San Antonio Breast Cancer Symposium (Abstract), 72(24 SUPPL 3) (Dec. 4-8, 2012)Applicant
• Higgins et al., “Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models” Anti-Cancer Drugs 15:503-512 (2004).Applicant
• Janku et al., “PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors” Mol Cancer Ther 10(3):558-65 ( 2011).Applicant
• Miller et al., “Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer” J Clin Oncol 29:4452-4461 ( 2011).Applicant
• Ndubaku et al., “Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-y1)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-y1]-1H-pyrazol-1-y1}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity” J. Med. Chem. 56:4597-4610 ( 2013)Applicant
• O'Shaughnessy et al., “Capecitabine/Taxane Combination Therapy: Evolving Clinical Utility in Breast Cancer” Clinical Breast Cancer 7(1):42-50 ( 2006).Applicant
• Ouchi et al., “Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models” Cancer Chemother. Pharmacol. 57:693-702 ( 2006).Applicant
• Samuels et al., “High frequency of mutations of the PIK3CA gene in human cancers” Science 304:554 (Apr. 23, 2004).Applicant
• Sawada et al., “Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts” Clin. Cancer Res. 4:1013-19 ( 1998).Applicant
• She et al., “Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling” PLoS ONE 3(8):1-10 ( 2008).Applicant
• Spoerke et al., “Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models” Clin Cancer Res 18:6771-83 ( 2012).Applicant
• Staben et al., “Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β Isoform” Bioorganic and Medicinal Chemistry Letters 23(9):2606-13 (May 1, 2013).Applicant
• Steinbach et al., “Combination and Sequential Antifungal Therapy for Invasive Aspergillosis: Review of Published In Vitro and In Vivo Interactions and 6281 Clinical Cases from 1966 to 2001” Clin. Inf. Dis. 37( SUPPL 3):S188-224 (Oct. 1, 2003).Applicant
• Sutherlin et al., “Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer” J Med Chem. 54(21):7579-87 ( 2011).Applicant
• Vadas, “Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases” Science Signaling 4(195):1-12 ( 2011).Applicant
• Wallin et al., “GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo” Clin Cancer Res 18:3901-11 ( 2012).Applicant
• Wallin et al., “GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway” Mol Cancer Ther. 10(12):2426-36 ( 2011).Applicant
• Wallin et al., “Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer” Sci Transl Med 2:48ra66 ( 2010).Applicant
• Weigelt et al., “PIK3CA mutation, but not PTEN loss of functionm, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs,” Oncogene 30:3222-33 ( 2011).Applicant
• Juric et al., “Phase Ib Study of the PI3K Inhibitor GDC-0032 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive Advanced Breast Cancer” ((SABCS 2013)).Applicant